CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Shareholder vote results
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change · Regulation FD disclosure
- 8-K Event Regulation FD disclosure · Other events
- 8-K Event Regulation FD disclosure
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Regulation FD disclosure
- 8-K Event Regulation FD disclosure · Other events
- 4 Planned sale Chief Medical Officer sold 45,316 shares at $8.76 ($396,995)
- 4 Planned sale Chief Scientific Officer sold 32,146 shares at $8.76 ($281,673)
- 4 Planned sale Chief Executive Officer sold 26,172 shares at an average $8.77 ($229,624)
- 4/A Planned sale Chief Technology Officer sold 31,278 shares at $8.82 ($275,947)
Page 6 of 22 · 422 filings